Bacterial Meningitis

Comprehensive Clinical Guide: Bacterial Meningitis

1. Introduction and Clinical Overview

Bacterial meningitis remains one of the most critical medical emergencies in clinical practice. It is defined as an acute, suppurative inflammation of the meninges—the protective membranes covering the brain and spinal cord—caused by the invasion of pathogenic bacteria into the subarachnoid space or the cerebrospinal fluid (CSF).

Unlike aseptic (viral) meningitis, bacterial meningitis is characterized by rapid progression, high mortality rates, and a significant risk of permanent neurological sequelae. Despite advancements in vaccination strategies (such as the widespread use of the Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis vaccines), the condition remains a global health burden, necessitating immediate recognition and aggressive therapeutic intervention.

2. Etiology and Pathophysiology

Etiological Agents by Age Group

The causative organisms for bacterial meningitis vary significantly based on the age of the patient and the presence of underlying immunocompromise or medical devices (e.g., shunts).

Pathophysiological Mechanism

The development of bacterial meningitis typically follows a multi-step cascade:

1. Colonization: Bacteria colonize the nasopharyngeal mucosa through the release of IgA proteases, which cleave host secretory IgA.
2. Invasion: Pathogens cross the mucosal barrier into the bloodstream, leading to bacteremia.
3. Blood-Brain Barrier (BBB) Penetration: Bacteria cross the BBB by exploiting the choroid plexus or through transcellular migration across the cerebral capillary endothelium.
4. Subarachnoid Proliferation: Once in the CSF, the lack of host immune defenses (complement and antibodies are low in CSF) allows for rapid bacterial replication.
5. Inflammatory Cascade: Bacterial lysis releases cell wall components (teichoic acid, lipopolysaccharide), triggering a massive release of pro-inflammatory cytokines (TNF-α, IL-1β). This results in increased vascular permeability, cerebral edema, elevated intracranial pressure (ICP), and potential neuronal damage.

3. Clinical Presentation and Staging

The Classic Triad

While the "classic" presentation includes fever, nuchal rigidity (neck stiffness), and altered mental status, this triad is present in less than 50% of adult patients. Clinicians must maintain a high index of suspicion for any patient presenting with acute febrile illness and neurological deterioration.

Clinical Signs

• Kernig’s Sign: Severe stiffness of the hamstrings causes an inability to straighten the leg when the hip is flexed to 90 degrees.
• Brudzinski’s Sign: Severe neck stiffness causes a patient's hips and knees to flex when the neck is flexed.
• Photophobia and Phonophobia: Increased sensitivity to light and sound due to meningeal irritation.
• Petechial/Purpuric Rash: Highly suggestive of N. meningitidis (meningococcemia).

Staging and Severity Grading

There is no universally accepted "staging" system like cancer; however, clinical severity is often assessed via the Glasgow Coma Scale (GCS) and the presence of systemic complications:
* Grade I: Alert, mild meningeal signs.
* Grade II: Lethargic, confusion, focal neurological deficits.
* Grade III: Comatose, seizures, signs of increased ICP (Cushing’s triad: hypertension, bradycardia, irregular respirations).

4. Diagnostic Evaluation

Lumbar Puncture (LP) and CSF Analysis

The gold standard for diagnosis is the analysis of CSF obtained via lumbar puncture.

Ancillary Testing

• Blood Cultures: Should be drawn prior to antibiotic administration.
• Neuroimaging (CT/MRI): Indicated before LP only if there is evidence of papilledema, focal neurological deficits, new-onset seizures, or immunocompromise to rule out mass effect/herniation.
• PCR/Latex Agglutination: Useful if the patient has received prior antibiotic therapy, which may render the CSF culture sterile.

5. Therapeutic Protocols and Risks

Empirical Therapy

Time is brain. Empirical therapy must be initiated immediately after blood cultures are obtained, even before the LP result is available.
* Adults (18–50): Vancomycin + Ceftriaxone.
* Adults (>50) or Immunocompromised: Vancomycin + Ceftriaxone + Ampicillin (to cover Listeria).
* Adjunctive Therapy: Dexamethasone (10mg IV) is recommended to reduce neurological sequelae, ideally given 15–20 minutes before or concurrent with the first dose of antibiotics.

Contraindications and Risks

• LP Contraindications: Unstable hemodynamics, local skin infection at the puncture site, or signs of impending brain herniation.
• Antibiotic Side Effects: Nephrotoxicity (Vancomycin), hypersensitivity (Cephalosporins), and potential for Clostridioides difficile infection.

6. Prognosis and Long-term Sequelae

Prognosis depends on the causative organism and the speed of treatment. Even with appropriate care, mortality ranges from 5% to 20%. Survivors may face:
* Sensorineural hearing loss (most common).
* Cognitive impairment and learning disabilities.
* Epilepsy/Seizure disorders.
* Focal motor deficits or gait abnormalities.

7. Frequently Asked Questions (FAQ)

1. Is bacterial meningitis contagious?
Yes, particularly N. meningitidis. Close contacts should receive chemoprophylaxis with Rifampin, Ciprofloxacin, or Ceftriaxone.

2. Why is Dexamethasone used?
It reduces the inflammatory response in the subarachnoid space caused by the lysis of bacteria when antibiotics are administered, thereby lowering the risk of cerebral edema and hearing loss.

3. What is the difference between meningitis and encephalitis?
Meningitis is the inflammation of the meninges (covering), whereas encephalitis is the inflammation of the brain parenchyma (tissue) itself.

4. Can you get meningitis from a viral infection?
Yes, viral (aseptic) meningitis is more common than bacterial, usually milder, and typically resolves without specific antibacterial treatment.

5. What is the significance of the petechial rash?
It indicates meningococcemia, where the bacteria have entered the bloodstream and are causing disseminated intravascular coagulation (DIC). This is a surgical/medical emergency.

6. When is a CT scan required before a lumbar puncture?
If there is suspicion of increased intracranial pressure, papilledema, recent head trauma, or focal neurological signs, a CT is required to prevent brain herniation during the LP.

7. How long should treatment last?
Duration varies by pathogen: S. pneumoniae (10–14 days), N. meningitidis (7 days), and Listeria (at least 21 days).

8. Are vaccines effective?
Yes, highly effective. Routine childhood vaccinations against Hib, S. pneumoniae, and N. meningitidis have drastically reduced the incidence of bacterial meningitis.

9. What are the long-term effects of meningitis?
Survivors often report "post-meningitis syndrome," which includes headaches, memory loss, fatigue, and hearing impairment.

10. Can I get meningitis twice?
Yes, especially if there is an anatomical defect (e.g., cerebrospinal fluid leak from a skull fracture) or a complement deficiency that makes an individual prone to recurrent N. meningitidis infections.

8. Clinical Summary Table: Differential Diagnosis

Disclaimer: This guide is intended for educational and clinical reference purposes for healthcare professionals. It does not replace institutional protocols or individual clinical judgment. Always consult current infectious disease guidelines (such as those from the IDSA) for the most recent updates on antibiotic resistance and therapeutic standards.